Abcam partners with A*STAR’s Institute of Molecular and Cell Biology

8/01/2015

Abcam plc, a global leader in the supply of life science research tools, announced today it has signed an exclusive partnership agreement with the Institute of Molecular and Cell Biology (IMCB), a research institute under the Agency for Science, Technology and Research (A*STAR), Singapore.

Under the terms of the agreement, Abcam will develop a range of RabMAb® antibody pairs against targets jointly selected by IMCB and Abcam, to be used by both organisations in the development of immunoassays for life scientists working in both research and in diagnostics.

Combining the biological research expertise at IMCB with Abcam’s RabMAb technology will enable rapid production of antibody pairs with a high level of affinity, specificity and validation. This will include antibody pairs to some of the most important targets in cytokine research, and to exciting novel proteins. The first antibody pairs are expected to be completed by August 2015 and available to the research market later in the year. This project represents the beginning of a planned multi-year collaboration between IMCB and Abcam.

Alan Hirzel, CEO, Abcam, said: “We’re excited about the opportunities that this collaboration will bring to life scientists. We are global leaders in making high quality antibodies with our RabMAb technology.  By continuing to establish important collaborations, we have the chance to extend our reach to new areas of research. IMCB’s unique R&D capabilities put us in an excellent position to quickly bring innovative immunoassays to global life science researchers, to accelerate the pace of scientific discoveries.”

Professor Wanjin Hong, Executive Director of IMCB, said: “We’re delighted to have signed this agreement. The collaboration will enable IMCB to use Abcam’s proven RabMAb technology and apply it in our R&D programs to advance future development and adoption of immunoassays in immunodiagnostics and therapeutics. In view of the significant R&D expertise and growing importance of the biologics industry in Singapore, this collaboration will help drive antibody discovery and development activities in the region. I am confident that A*STAR and the scientific community will benefit from this promising partnership.”

To find out more, visit www.abcam.com


About A*STAR’s Institute of Molecular and Cell Biology (IMCB)

The Institute of Molecular and Cell Biology (IMCB) was launched on 23 January 1985, with its official opening ceremony held on 2 October 1987 at the National University of Singapore. It subsequently became an autonomous research institute of A*STAR, moving to Biopolis in 2004. IMCB's vision is to be a premier cell and molecular biology institute which addresses the mechanistic basis of human diseases and its mission is to conduct cutting-edge discovery research in disease pathways; to groom early career researchers to be future leaders in research; and to collaborate with medical and industry communities for research impact. IMCB plays an important role training and recruiting scientific talents, and has contributed to the development of other research entities in Singapore. Its success in fostering a biomedical research culture in Singapore has catalysed Singapore's transformation into an international hub for biomedical research, development and innovation.

Funded primarily by the Biomedical Research Council of A*STAR, IMCB's current discovery research includes cell biology in health and disease; animal models of development & disease; cancer & stem cell genetics & genomics; and structural biology & drug discovery. IMCB's translational research includes humanised model organisms for human diseases; systems approach for disease target identification & validation; and protein engineering & antibody development for diagnostics & therapeutics. Research activities at IMCB are supported by cutting edge infrastructure and facilities including quantitative proteomics; humanised mice; mouse models of human cancer; protein crystallography X-ray; zebrafish for drug metabolism & toxicology; advanced molecular histopathology; imaging & electron microscopy; and DNA sequencing.

For more information, please visit: www.imcb.a-star.edu.sg

*******

Contacts:
Abcam
Francesca Axe
T: +44 (0) 1223 696000

Media enquiries
Katie Odgaard
Zyme Communications
E: katie.odgaard@zymecommunications.com
T: +44 (0) 7787 502 947

___________________________________________________

Abcam plc

As an innovator in reagents and tools, Abcam’s purpose is to serve life science researchers globally to achieve their mission, faster.

Abcam plc directory information

Back to Search

Newsletter signup

Jobsletter signup